Haptoglobin 2-2 phenotype is a risk factor for type 2 diabetes in Ghana

Journal of Atherosclerosis and Thrombosis

Volumn 13, Issue 2, 2006, Pages 90-94

  Quaye, Isaac K ^a   Ababio, Grace ^a   Amoah, Albert G ^a  

^a UNIVERSITY OF GHANA   (Ghana)

Author keywords

Diabetes; Ghana; Haptoglobin

Indexed keywords

HAPTOGLOBIN; LIPID;

ADULT; ALLELE; ARTICLE; BLOOD; CASE CONTROL STUDY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; GHANA; HUMAN; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; RISK FACTOR;

ADULT; ALLELES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; GENE FREQUENCY; GHANA; HAPTOGLOBINS; HUMANS; LIPIDS; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 33746501858     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13.90     Document Type: Article

References (34)

1. Alberti KG, and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med, 1998; 15:539-553.
2. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on th Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997; 20:1183.
3. Zimmet P, Alberti KG, and Shaw J: Global and societal implications of the diabetes epidemic. Nature, 2001; 414:782.
4. Amoah A, Owusu S, and Adjei S: Diabetes in Ghana: a community based prevalence study in Greater Accra. Diabetes Res and Clin Pract, 2002; 56:197.
5. King H, Aubert RE, and Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 1998; 21:1414.
6. Abuissa H, Bell DSH, and O'Keefe Jr JH: Strategies to prevent type 2 diabetes. Curr Med Res and Opinion, 2005; 21:1107.
7. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, and Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without myocardial infarction. N Engl J Med, 1998; 339:229.
8. Coutinho M, Gerstein H, Wang Y, and Yusuf S: The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care, 1999; 22:233.
9. Varughese GI, Tomson J, and Lip GYH: Type 2 diabetes mellitus: a cardiovascular perpective. Int J Clin Prac, 2005; 59:798.
10. Sjoholm S, and Nystrom T: Endothelial inflammation in insulin resistance. Lancet, 2005; 365:610.
11. Libby P: Inflammation in atherosclerosis. Nature, 2002; 420:868.
12. Fernandez-Real JM, and Ricart W: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev, 2003; 24:278.
13. UK Prospective Diabetes Study Group: Ethnicity and cardiovascular disease:the incidence of myocardial infarction in white, south Asian and afro-Caribbean patients with type 2 dibetes. Diabetes Care, 1998; 21:1271.
14. Miller-Lotan R, Herskowitz Y, Kalet-Litman S, Nakhoul F, Aronson D, Zoabi R, Asaf R, Ben-Izhak O, Sabo E, Lim SK, Baumann H, Berger FG, and Levy AP: Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev, 2005; 21:332.
15. Levy A, Roguin A, and Hochberg Iea: Haptoglobin phenotypes and vascular complications in diabetes. N Engl J Med, 2003; 343:969.
16. Awadallah SM, and Hamad H: The prevalence of type II diabetes is haptoglobin phenotype independent. Cytobios, 2000; 101:145.
17. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, and Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Community Study): a cohort study. Lancet, 1999; 353:1649.
18. Stern MP, Ferrell RE, Rosenthal M, Haffner SM, and Hazuda HP: Association between NIDDM, RH blood group, and haptoglobin phenotype. Results from San Antonio Heart Study. Diabetes, 1986; 35:387.
19. Melamed-Frank M, Lache O, Enav B, Szafranek T, Levy N, Ricklis R, and Levy A: Structure-function analysis of the antioxidant properties of haptoglobin. Blood, 2001; 98:3693.
20. Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, and Landis RC: Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and hem oxygenase-1 synthesis: antiinflarnmatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res, 2004; 94:119.
21. Wang Y, Kinzie E, Berger F, Lim S, and Baumann H: Haptoglobin, an inflammation-inducible plasma protein. 2001.
22. Tseng CF, Lin CC, Huang HY, Liu HC, and Mao SJ: Antioxidant role of human haptoglobin. Proteomics, 2004; 4:2221.
23. Lim SK, Ferraro B, Moore K, and Halliwell B: Role of haptoglobin in free hemoglobin metabolism. Redox Rep, 2001; 6:219.
24. Maeda N: DNA polymorphisms in the controlling region of the human haptoglobin genes: a molecular explanation for the haptoglobin 2-1 modified phenotype. Am J Hum Genet, 1991; 49:158.
25. Chakraborty R, Ferrell RE, Stern MP, Haffner SM, Hazuda HP, and Rosenthal M: Relationship of prevalence of non-insulin dependent diabetes mellitus to Amerindian admixture in the Mexican Americans of San Antonio, Texas. Genet Epidemiol, 1986; 3:435.
26. Connell G, and Smithies O: Human haptoglobins: estimation and purification. Biochem J, 1959; 72:115.
27. Mancia G: The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol, 2005; 42:S17.
28. Langlois MR, and Delanghe JR: Difference in hemoglobin-binding ability of polymers among haptoglobin phenotypes. Clin Chem, 1997; 43:2012.
29. Levy AP, Hochber I, Jablonski K Resnick HE, Lee ET, Best L, and Howard BV: Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J AM Coll Cardiol, 2002; 40:1984.
30. Halliwell B: Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic Res, 1999; 31:261.
31. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, and Levy AP: Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circulation Res, 2003; 92:1193.
32. Kristiansen M, Graversen J, and Jacobsen C, et al: Identification of the haemoglobin scavenger receptor. Nature, 2001; 409:198.
33. Sadrzadeh SM, Graf E, Panter SS, HaUaway PE, and Eaton JW: Hemoglobin: a biologic Fenton reagent. J Biol Chem, 1984; 259:14354.
34. Venerando B, Fiorilli A, Croci G, Tringali C, Goi G, Mazzanti L, Curatola G, Segalini G, Massaccesi L, Lombardo A, and Tettamanti G: Acidic and neutral sialidase in the erythrocyte membrane of type 2 diabetic patients. Blood, 2002; 99:1064.